|
|
Blood, 30 April 2009, Vol. 113, No. 18, pp. 4135-4136.
 Previous Article | Table of Contents | Next Article 
VASCULAR BIOLOGY
Comment on Kärkkäinen et al, page 4468
Lymphangiogenesis factors: a target for therapy?
Arjan W. Griffioen
MAASTRICHT UNIVERSITY
In this issue of Blood, Kärkkäinen and colleagues demonstrate, using a VEGF-D transgenic mouse model, that overexpression of human VEGF-D induces a proangiogenic phenotype, increases regeneration after ischemic injury, and also induces the formation of tumors.
Vascular endothelial cell growth factor D (VEGF-D) was identified in the mid -1990s as a c-fos–induced growth factor sharing structural and functional characteristics with VEGF-C and displaying lymphangiogenic properties through activation of the lymph vasculature receptor VEGFR-3.1,2 In humans, VEGF-D binds to VEGFR-3 as well as to VEGFR-2, of which the latter is the receptor for VEGF-transducing signals leading to formation of blood vessels. The study by Kärkkäinen et al, which reports the generation of human VEGF-D transgenic mice using a method based on perivitelline oocyte injection of a lentiviral vector expressing the growth factor, provides new insight into the biology of VEGF-D.3 The transgenic mice, constitutively expressing VEGF-D in many organs, clearly demonstrate a proangiogenic phenotype with enhanced blood vessel capillary density in muscle tissue while a lack of increased numbers of lymphatic capillaries suggest no effect on lymphangiogenesis. The enhanced healing capacity of transgenic mice after ischemic injury was also suggested to be mainly due to VEGFR-2 signaling and enhanced blood vessel formation. These results are consistent with earlier studies where knockout approaches were used, demonstrating that VEGF-D does not have a major lymphangiogenesis function.4 This study by Kärkkäinen et al, as well as studies by others, may suggest the potential for growth factor therapy of ischemic diseases. In addition, discussions on the use of therapeutic lymphangiogenesis for diseases with associated lymphedema after surgery or radiotherapy are ongoing. Although this is an attractive approach, (lymph-)angiogenic growth factors can enhance vascular permeability, which may pose an additional problem.
In the present study, it was observed that mice with human VEGF-D incorporated in their genome developed spontaneous tumors in epithelia with a preference for induction of mammary gland adenocarcinomas. This interesting and unexpected finding may limit the therapeutic use of VEGF-D. Therapeutic intervention by neutralization of VEGF-D for diseases characterized by excessive angiogenesis, such as cancer, may therefore be a more promising approach. Indeed, inhibition of metastatic spread, microhemorrhage, and collapse of tumor vessels has been described in mice injected with blocking monoclonal antibodies5 or soluble VEGFR-3.6
Although it was reported before that VEGF-D can facilitate tumor growth and support metastasis formation, probably due to enhanced vessel/tumor cell interaction surface, it is very interesting to question how VEGF-D can give rise to spontaneous tumors. It suggests that either the growth factor itself can transform normal epithelial cells into tumor cells — a hypothesis that is currently considered unlikely — or that normal epithelial cells are continuously challenged by genetic or epigenetic alterations, having more chance to result in tumor cells (normally a very rare event) when a more angiogenic environment is available. In the latter situation, tumor growth may be supported by better supply of oxygen and nutrients, by enhanced vascular permeability, a beneficial cytokine/chemokine milieu, or by a changed adhesion molecule profile. Another possibility is the VEGF-D–mediated generation of an immune-privileged situation. Indeed, VEGF-D has been reported to contribute, in a concerted action with other angiogenic growth factors, to endothelial cell anergy and subsequent escape from immune surveillance.7 All these conditions are supportive for an anti–VEGF-D strategy to intervene with tumor growth. Such an approach would potentially have the same problems as current anti-VEGF strategies in the clinic,8 such as induction of drug-induced resistance, but this may be overcome by combining different strategies of therapy. The paper by Kärkkäinen et al definitely underscores the importance of VEGF-D in the regulation of angiogenesis and suggests an opportunity for the development of new and innovative medical technology for cancer and other human diseases.
Footnotes
Conflict-of-interest disclosure: The author declares no competing financial interests. 
REFERENCES
- Orlandini M, Marconcini L, Ferruzzi R, et al. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc Natl Acad Sci U S A. 1996;93:11675–11680.[Abstract/Free Full Text]
- Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A. 1998;95:548–553.[Abstract/Free Full Text]
- Kärkkäinen A-M, Kotimaa A, Huusko J, et al. Vascular endothelial growth factor-D transgenic mice show enhanced blood capillary density, improved postischemic muscle regeneration, and increased susceptibility to tumor formation. Blood. 2009;113:4468–4475.[Abstract/Free Full Text]
- Baldwin ME, Halford MM, Roufail S, et al. Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Mol Cell Biol. 2005;25:2441–2449.[Abstract/Free Full Text]
- Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 2001;7:186–191.[CrossRef][Medline]
[Order article via Infotrieve]
- Kubo H, Fujiwara T, Jussila L, et al. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood. 2000;96:546–553.[Abstract/Free Full Text]
- Bouma-ter Steege JC, Baeten CI, Thijssen VL, et al. Angiogenic profile of breast carcinoma determines leukocyte infiltration. Clin Cancer Res. 2004;10:7171–7178.[Abstract/Free Full Text]
- Griffioen AW. Therapeutic approaches of angiogenesis inhibition: are we tackling the problem at the right level? Trends Cardiovasc Med. 2007;17:171–176.[CrossRef][Medline]
[Order article via Infotrieve]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Vascular endothelial growth factor-D transgenic mice show enhanced blood capillary density, improved postischemic muscle regeneration, and increased susceptibility to tumor formation
- Anna-Mari Kärkkäinen, Antti Kotimaa, Jenni Huusko, Ivana Kholova, Suvi Elina Heinonen, Anna Stefanska, Marike Hinke Dijkstra, Hanna Purhonen, Eveliina Hämäläinen, Petri Ilmari Mäkinen, Mikko Petri Turunen, and Seppo Ylä-Herttuala
Blood 2009 113: 4468-4475.
[Abstract]
[Full Text]
[PDF]
|
|
